Systemic targeted radionuclide therapy: Potential new areas
- 1 October 2006
- journal article
- review article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 66 (2) , S74-S82
- https://doi.org/10.1016/j.ijrobp.2005.05.029
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Monoclonal antibodies as therapeutic agents for cancerThe Lancet Oncology, 2004
- A clinical and scientific overview of tositumomab and iodine I 131 tositumomabSeminars in Oncology, 2003
- Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2002
- Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphomaSeminars in Oncology, 2002
- Effect of lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemiaCancer, 1994
- Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow SupportNew England Journal of Medicine, 1993
- Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) AntibodyNew England Journal of Medicine, 1993
- THE USE OF RADIOLABELED ANTI-CD33 ANTIBODY TO AUGMENT MARROW IRRADIATION PRIOR TO MARROW TRANSPLANTATION FOR ACUTE MYELOGENOUS LEUKEMIATransplantation, 1992
- Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01.Journal of Clinical Oncology, 1991
- A phase 1a clinical trial of LYM‐1 monoclonal antibody serotherapy in patients with refractory b cell malignanciesHematological Oncology, 1989